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Abstract
Purpose—The Scripps Idiopathic Diseases of huMan (IDIOM) study aims to discover novel 
gene-disease relationships and provide molecular genetic diagnosis and treatment guidance for 
individuals with novel diseases using genome sequencing integrated with clinical assessment and 
multidisciplinary case review.
Methods—Here we describe the IDIOM study operational protocol and initial results.
Results—121 cases underwent first tier review by the principal investigators to determine if the 
primary inclusion criteria were satisfied, 59 (48.8%) underwent second tier review by our 
clinician-scientist review panel, and 17 (14.0%) patients and their family members were enrolled. 
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60% of cases resulted in a plausible molecular diagnosis. 18% of cases resulted in a confirmed 
molecular diagnosis. 2 of 3 confirmed cases led to the identification of novel gene-disease 
relationships. In the third confirmed case, a previously described but unrecognized disease was 
revealed. In all three confirmed cases, a new clinical management strategy was initiated based on 
the genetic findings.
Conclusions—Genome sequencing provides tangible clinical benefit for individuals with 
idiopathic genetic disease, not only in the context of molecular genetic diagnosis of known rare 
conditions, but also in cases where prior clinical information regarding a new genetic disorder is 
lacking.
Keywords
clinical sequencing; rare disease; genomics; undiagnosed diseases; genome sequencing
INTRODUCTION
The traditional approach to rare, severely disabling medical conditions frequently leaves the 
affected individual without a diagnosis and effective treatment. Patients with such conditions 
can remain ill and endure a “diagnostic odyssey” for years, which is not only difficult for 
such individuals and their family, but can also be very cost inefficient. Many have previously 
suggested the utility of genomic information for diagnosing and treating such conditions, 
and early evidence of the successful application of whole exome sequencing (WES) and 
whole genome sequencing (WGS) for such purposes is emerging1–6. Of the rare likely 
genetic diseases that have already been described, approximately half have yet to be linked 
to a causal gene (termed here: “idiopathic diseases”)7. Estimates of the total number of rare 
likely genetic diseases based on the number of known disease causing and essential genes 
have resulted in predictions of between 7,000 to 15,000 disorders, suggesting many rare 
genetic diseases have yet to be described8. While the application of genome sequencing to 
the molecular genetic diagnosis of previously described rare Mendelian disorders is 
essentially proven, the utility of genome sequencing in novel diseases has not been 
systematically explored. For example, of the ~100 patients successfully diagnosed by the 
National Institutes of Health Intramural Undiagnosed Disease Program (NIH UDP) (20–
25% of the total enrolled), 15 cases (~3.5% of total enrolled) correspond to novel gene 
associations for previously described diseases, and only 2 cases (<1% of total enrolled) 
correspond to previously unknown diseases9.
The Scripps Idiopathic Diseases of huMan (IDIOM) study was initiated in 2011. IDIOM 
was, in large part, modeled after the NIH UDP, with a few exceptions. The primary 
exception being that we focus exclusively on cases that do not fit a previously described 
phenotype, or cases where the disorder matches a previously described phenotype and all 
known genetic causes of the disorder have been ruled out. In other words, only 17 of 100 
successfully diagnosed cases in the NIH UDP would have qualified for the IDIOM study (15 
corresponding to a novel gene associations for previously described diseases, 2 cases 
corresponding to previously unknown diseases). The application of genome sequencing to 
molecular genetic diagnosis in this sub-population of individuals presents some unique 
challenges both in terms of the evaluation of cases and appropriateness for the IDIOM 
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program, as well as for the ultimate return of genetic results. In this report we provide a 
description of IDIOM study procedures, the initial results from the first three years of 
operation, and the clinical benefit achieved by those realizing a confirmed genetic diagnosis.
METHODS
Recruitment and Screening
The Scripps Idiopathic Diseases of huMan (IDIOM) Study (IRB-11-5723) was approved by 
the Scripps Institutional Review Board in 2011. A separate informed consent was attained 
for genome sequencing vs. treatment response monitoring. Recruitment for IDIOM was 
done through announcements to physicians within the Scripps Health system and advocacy 
groups, announcements via local media10,11, and word of mouth. A number of online 
sources were utilized such as the CTSA Vanderbilt-hosted Researchmatch.org, “reach out” 
to leaders of the NIH UDP, RARE Project, and National Organization for Rare Diseases. 
Scripps Health hosts a landing page for the IDIOM study that includes study criteria and 
coordinator contact information. The trial is also listed on clinicaltrials.gov (http://
clinicaltrials.gov/ct2/show/NCT01440218). Since initial financial support for our study was 
limited, we have been conservative with respect to our recruitment efforts so as not to be 
inundated with a large number of referrals that we would not have the resources to fund.
Inclusion criteria for the study are the following: (1) the patient has a grave or serious 
condition that is undiagnosed despite extensive medical and genetic evaluation – for patients 
with a likely clinical diagnosis, at minimum, a gene panel test is required to rule out known 
genetic causes of the disorder; (2) the patient’s condition is potentially “actionable” or 
amenable to treatment – this is a subjective judgment by the physician review panel that 
typically only excludes individuals with severe dysmorphologies; (3) the condition appears 
genetic in origin; (4) the patient’s anticipated life expectancy is consistent with the study 
timeline for sequencing; and (5) the patient has a physician champion who is willing to work 
with the research team and take responsibility for returning genetic results to the patient.
In order to be considered, patients or their referring physician provide a short clinical 
summary and all available medical records. Referrals undergo an initial review by the 
IDIOM study coordinator. Typically, cases with complete medical records undergo another 
round of internal review by core study investigators, often via email, and those that appear to 
meet inclusion criteria are forwarded for review by the IDIOM Clinician-Scientist Review 
Panel.
Clinician-Scientist Review Panel
Our clinician-scientist review panel is made up of approximately 12 practicing physicians, as 
well as a research team consisting of bioinformatics and genetic analysis specialists, 
physicians who utilize genetics extensively in clinical practice, sequencing experts, ethicists, 
clinical psychologists, and research nurses. The Director of the Scripps IRB is also a 
member of the panel. The clinical disciplines represented among the physician members 
include, though are not limited to, the following: neurology, rheumatology, internal 
medicine, allergy/immunology, cardiology, medical oncology/hematology, and 
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gastroenterology/hepatology. For a quorum we required the presence of at least 5 physicians 
and 2 bioinformatics or sequencing experts. Selection of cases is made based on majority 
vote, however, in almost all instances to date, decisions to enroll a patient have been 
unanimous. The meetings typically last 1.5 hours, and between 3 and 4 cases are usually 
reviewed per session. We encourage and allow for, but do not require, the physician 
champion of patients whose cases are being reviewed to be available during the meeting 
(either in person or via teleconference) in order to answer questions and interface with the 
panel.
Consent and Enrollment
Once a case has been selected by the clinician-scientist panel, our nurse study coordinator 
consents the patient and family members. Usually the participants that comprise a case are 
those in a trio (i.e., proband, mother, and father), but occasionally other biological family 
members are sequenced, and in these instances, it is usually a sibling of the proband or 
parents.
Importantly, a primary issue raised in the literature regarding patient consent for WES and 
WGS studies is the identification of ‘incidental’ or ‘secondary’ findings (i.e., genomic 
findings of clinical relevance that are not recognized as being associated with the presenting 
disease/condition). We have deemed that best practices are yet to be determined by empirical 
data12 and thus, have elected to only return results directly relevant to the presenting 
indication. If we should inadvertently discover incidental findings that could have an effect 
on the patient’s health, the results would be reviewed by our clinician-scientist review panel, 
who would adjudicate how to proceed with informing the physician champion and patient13.
For selected cases, we also ask the patient’s physician champion (usually the referring 
physician) to sign an agreement of participation that stipulates that s/he will commit to: (a) 
regular interactions with the research team; (b) acceptance of responsibility for return of 
genomic results to the patient; (c) acceptance of any clinical decision-making on the basis of 
any results provided; and (d) completion of brief baseline and follow-up questionnaires 
and/or interviews pertaining to the study.
Sequence Data Generation, Analysis and Interpretation
Once cases have been selected and patients and family members are consented for 
participation, blood is drawn and brought to our lab at STSI for sequencing of the proband 
and biological family members. Once parentage is confirmed, WES is performed for the 
detection of coding variants, and low pass WGS is performed for the detection of structural 
and copy number variants. Target WES coverage is ~100× and target low pass WGS 
coverage is ~5×. Other published papers have described this data generation protocol in 
detail, as well as our methods for analysis and interpretation14–17. If necessary, especially 
for indels or variants with limited coverage in any family members, Sanger sequencing is 
utilized to confirm candidate causal variants. The theoretical target breakpoint resolution for 
low pass WGS detection of CNVs is 200bp given a bin size of 200–300bp and target 
coverage of 4–8×18. This resolution allows for the identification of small events such as 
single exon deletions. In practice, this resolution was achieved; however manual inspection 
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of read level data of the WES and low pass WGS data was required due to false positive 
variant calls. Ultimately, algorithms such as Genome STRiP, which utilize population level 
data to account for systematic read depth biases, are necessary to improve the reliability of 
these results19.
Sequencing is performed in a research laboratory with results ultimately returned to the 
physician champion. Given the exploratory nature of these cases, results as well as the 
consent process include an explanation that any findings are unproven in nature and 
performed in an uncertified laboratory. Our case selection process, i.e. the focus on novel 
phenotypes and novel gene-disease relationships, eliminates from consideration individuals 
likely to benefit from certified laboratory tests, and we provide suggestions for the 
appropriate alternative commercial certified laboratories for these patients. Similarly, if a 
known pathogenic variant is identified, recommendations for CLIA confirmation via 
validated tests (rather than CLIA confirmation in a certified lab without the specific 
validated test) are provided.
Individualized Genomic Report and Return of Results
Once results for a specific patient have been generated, an individualized genomic report is 
prepared for dissemination to our Clinician-Scientist Review Panel and the patient’s 
physician champion. The panel has the opportunity to raise any issues related to the specific 
case prior to disclosing results. In all cases, one or more consultations between members of 
the panel and the physician champion are arranged to allow him/her to have any questions 
answered and have the results verbally conveyed. In cases where a plausible diagnosis is 
identified, the discussion with the physician champion centers on whether or not the findings 
should change clinical management of the patient. Any new treatment offered to the patient 
is ultimately the treating physician’s decision. Certified genetic counselors are available on 
demand if requested.
Follow-up Studies
While STSI houses the facilities required for functional studies, specialized assays are often 
required for appropriate functional characterization of candidate disease causative variants. 
Thus, to functionally characterize findings in IDIOM, appropriate follow-up studies are 
tailored to the disease and gene in question, and we generally do this in collaboration with 
other laboratories specialized in the study of a particular gene or gene family. STSI is also 
uniquely facile in the use of wireless sensors. Thus, when appropriate for select patients, we 
design and deploy N-of-1 studies for quantitative assessment of physiologic metrics. 
Furthermore, we have used such approaches to objectively determine whether there has been 
a therapeutic response to treatment once a molecular diagnosis is made and a genomically-
indicated treatment initiated.
RESULTS
Referrals and Enrolled Patients
In the first three years of the IDIOM program, 121 patient referrals were received, 59 
(48.8%) have undergone second tier review by our clinician-scientist review panel, and 17 
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(14.0%) patients and their family members have been enrolled. Referrals have come from 
over 16 different U.S. states, and we have received a number of international referrals.
Demographic statistics and comparisons for referred versus reviewed versus enrolled 
patients are shown in Table 1. Across all of the 121 patients referred to date, 31.9% were 
children (i.e., <18 years of age), 59.4% female, and 36.7% physician referred (versus self or 
family referred). As shown, however, those cases that underwent panel review and/or that 
were eventually enrolled were younger and more likely to be physician referred. Self/family 
referred subjects, if selected, were required to secure a physician champion.
Figure 2 shows the medical specialties/phenotypes represented among the 121 patients 
referred to date for which clinical information was available. By far the most common 
category has been neurologic disorders, encompassing 32.1% of referrals, with hematology/
oncology, allergy/immunology, cardiology, and gastroenterology making up the top five 
broad phenotypic categories.
The major reasons for exclusion of cases have been identification of cases that meet a 
previously described phenotype and exclusion of cases that do not appear to be genetic. 
Cases that meet a previously described phenotype, e.g. when the submitted case already has 
a likely clinical diagnosis, are referred to an appropriate laboratory, or appropriate test, upon 
exclusion. If all known genetic causes of the previously described phenotype are ruled out, 
the case would be reconsidered. Exclusion of cases not likely to be genetic is usually based 
on one of the following reasons; 1) the panel feels the condition is likely explained by an 
environmental insult or infectious disease, 2) unusual circumstances surrounding birth, for 
example pre-term birth or complications during birth – suggesting non-genetic 
developmental defect, 3) lack of objectively documented findings either on physical 
examination or testing, especially subjective symptoms that cannot be connected via 
dysfunction of a specific biological system.
Molecular Diagnosis
Detailed descriptions of each case and the findings are provided in the Supplemental Text. 
Of the cases that have been processed to date, we have arrived at a plausible molecular 
diagnosis in approximately 60% and a confirmed molecular diagnosis in approximately 18% 
of all cases (Table 2). A plausible molecular genetic diagnosis is defined as meeting the 
following criteria: 1) identified variants segregate in the family and reference populations in 
a manner consistent with the segregation of the disease in the family and incidence of the 
disorder in the general population, 2) variants influence the coding/splicing of a protein 
coding gene, and 3) the gene can be connected to the presenting phenotype through similar 
human disorders caused by mutation in the same gene or via genome-wide association 
studies, the gene can be connected to the presenting phenotype through close functional 
interaction with genes known to cause the presenting phenotype or similar phenotype, or the 
gene can be connected to the presenting phenotype via animal studies. Of the 60% of cases 
meeting this criteria, we have aggressively pursued functional validation in cases where the 
variant is of de-novo origin, further increasing confidence in the finding and maximizing 
yield of downstream effort with collaborators. In 2 cases so far we have completed 
functional and statistical confirmation of a novel gene-disease relationship via the 
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identification of additional affected subjects with mutations in the same gene as well as 
functional confirmation of gene dysfunction 15,17, and in one instance a previously 
identified pathogenic variant was revealed. In all three cases, a new management strategy 
(pharmacological treatment) was initiated based on the findings, and we are currently 
closely monitoring this patient’s response to the therapy.
Clinical Management Strategy Changes and Benefit
IDIOM1 presented with a complex movement disorder, described in detail in Chen et al. 
201415, ultimately confirmed to be due to a gain of function de-novo mutation in ADCY5, 
and potentially modified by additional mutations in DOCK3 (unconfirmed). An N-of-1 style 
trial to monitor night time abnormal movements during treatment with various compounds 
indicated by gain of function in ADCY5 (ropinirole, carbamazepine, tetrabenazine, 
diazepam) with appropriate run-in and washout periods was initiated. The trial was halted 
upon request subsequent to initiation of the first agent, diazepam, after complete resolution 
of night-time myoclonic jerks. Diazepam has been previously shown to abrogate stress 
tolerance in ADCY5 null mice20. Figure 3 presents a dramatic and sustained resolution of 
abnormal movements after initiation of diazepam treatment, as captured by a movement-
tracking device.
IDIOM9 presented with a complex seizure disorder with drop attacks, described in detail in 
Torkamani et al. 201417, ultimately confirmed to be due to a de-novo mutation in potassium 
channel KCNB1 which changed ion selectivity. As a result, in order to control potassium 
levels carefully, the subject was placed on a specialized diet and kept hydrated. Thus, a 
change in the clinical management strategy was initiated, with unconfirmed clinical benefit. 
Unfortunately, no particular anti-epileptic drug is indicated from the genetic results, and 
comparison to patients with a similar underlying genetic cause of epilepsy did not reveal a 
specific and efficacious therapeutic strategy21 (personal communication). An anecdotal 
reduction in drop attacks has been noted by the treating physician, though longer follow-up 
is required to confirm a sustained benefit.
IDIOM15 presented with hypertrichotic osteochondrodysplasia (excess hair growth on scalp, 
forehead, and face), a gene defect that was ultimately attributed to a known pathogenic de-
novo ABCC9 mutation. Dominant missense mutations in ABCC9 cause gain-of-function 
channel opening and implicate a number of different channel blockers as potential 
therapeutic avenues22. Treatment modifications have been initiated with long-term follow-up 
required to confirm a sustained benefit.
DISCUSSION
The Scripps Idiopathic Diseases of huMan (IDIOM) study aims to discover novel gene-
disease relationships and provide molecular genetic diagnosis and treatment options for 
individuals with idiopathic diseases using genome sequencing integrated with clinical 
assessment and multidisciplinary case review. The primary difference relative to other 
similar programs is our exclusive focus on novel gene-disease relationships. In fact, 
candidates with phenotypes similar to those previously described must have had known 
genes potentially mediating their phenotype ruled out before consideration as an IDIOM 
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subject. While our protocol exclusively focuses on novel diseases or novel gene-disease 
relationships, it is remarkable that we demonstrate an initial rate of novel and confirmed 
genetic discoveries similar to that reported by programs focused on standard molecular 
genetic diagnosis via genome sequencing (20–25%)4,9,23,24. Although the volume, rate, and 
efficiency at which novel gene-disease relationships can be confirmed is lower than that 
achievable by standard molecular genetic diagnosis via genome sequencing, these results 
suggest that genome sequencing has the potential to be at least as efficacious in providing 
genetic diagnosis for individuals with previously undescribed disease as it is for individuals 
with known Mendelian disorders – with an upper limit to the diagnostic yield of ~60% 
(± 23% – 95% confidence interval) as informed by our plausible findings. However, we must 
acknowledge that a direct comparison between the diagnostic rate of these programs cannot 
be made since the rate depends heavily upon the ascertainment of the cohort in question.
The conversion of novel, plausible, gene-disease relationships to confirmed and validated 
genetic diagnoses should increase the yield of clinical genome sequencing programs above 
the current 20–25% diagnostic rate. In fact, individuals sequenced at clinical genome 
sequencing centers have initiated contact with the Scripps IDIOM investigators, subsequent 
to publication of our confirmed novel gene-disease relationships, bringing to light the fact 
that some individuals do not achieve a genetic diagnosis due to a lack of recognition of the 
causal variant in genome sequence data by those reporting the results, rather than any deficit 
in the technical identification of the causal variant. For example, we have received inquiries 
from two individuals with negative clinical exome results who had the same de-novo 
ADCY5 mutation as described in our IDIOM1 case – reported, correctly at the time of the 
test, as a variant of unknown significance in the clinical exome report. It remains to be seen 
what the relative contribution of deficits in technical variant identification vs. deficits in 
knowledge of gene-disease relationships is to the lack of molecular genetic diagnosis in 
those ~75% of individuals not receiving a genetic diagnosis after clinical genome 
sequencing. Ultimately, the contribution of novel gene-disease relationships to increasing the 
yield of clinical genome sequencing requires conversion of plausible findings to a confirmed 
genetic diagnosis through the identification of additional cases. This has been difficult to 
achieve but may be facilitated though services such as Matchmaker Exchange 
(matchmakerexchange.org). Comprehensive and accessible collection of phenotypic 
characteristics is key to achieving this goal.
In our study, all confirmed molecular genetic diagnoses achieved a tangible clinical benefit 
above and beyond the utility achieved simply by ending a diagnostic odyssey. However, 
there have been some notable challenges in the context of this project. For example, we 
often have families request other information, frequently referred to as secondary or 
“incidental findings” from their genomic analysis, and the research team has engaged in 
substantial discussion as to whether findings that do not pertain to the patient’s presenting 
condition should be assessed and reported back to the physician and/or patient. At this time, 
given that sequencing is performed in an uncertified laboratory for a pre-specified purpose, 
we do not to return information that is not directly applicable to the presenting condition. We 
have also observed wide variability in the extent to which our “physician champions” have 
knowledge of and comfort with genomic information, which has a major influence on the 
amount of information these clinicians then share with patients and the ultimate clinical 
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utility of any findings. A multi-disciplinary clinician-scientist review panel has been 
essential to supporting physician champions as well as selection of appropriate cases most 
likely to benefit from genome sequencing. Finally, the transmission of information back to 
physician champions, clearly indicating the suggestive nature of the majority of our findings, 
has been essential to managing expectations of the physician champions and ultimately the 
enrolled subjects.
An important area of improvement, especially for this program with no specific disease 
focus, is to objectively link the symptoms presented by study subjects to previously 
described conditions. Any physician-scientist review panel is unlikely to represent 
specialties covering the broad range of conditions referred to the program, thus similarities 
to previously described conditions (as exemplified by our hypertrichotic 
osteochondrodysplasia case) can be missed. In a more comprehensive program, spanning 
molecular genetic diagnosis of undiagnosed disease and discovery of novel gene-disease 
relationships in idiopathic disease, automated systems for phenotype matching can provide 
both known genetic conditions and gene-disease relationships that should be considered for 
confirmatory molecular diagnosis, as well as grounding for exploration of novel gene-
disease relationships through implicated biological processes and genetic networks 
mediating those processes. We believe this could provide a model for the unbiased 
application of genome sequencing across all rare genetic disorders, known and unknown.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Phenotypic Distribution of Case Referrals
The distribution of phenotypes referred to the Scripps IDIOM study is plotted based on the 
subset of N = 106 referrals for whom we were able to obtain complete data.
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Figure 2. Tracking of Therapy Response in IDIOM1
Actigraphy based motion tracking demonstrates a dramatic and sustained decrease in night 
time myoclonic jerks due to gain of function mutation in ADCY5. Day 0 – 6 represents the 
last week of a three week run-in period to wash-out previous therapies. Diazepam is initiated 
on day 6 (arrow) with a dramatic reduction tremors sustained for over two months. Tremors 
are defined as movement magnitude >0 sustained for greater than 60 seconds.
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Table 2
Genetic Diagnoses of Enrolled Cases
Case Phenotype Outcome Plausible
Diagnosis
Functional
Confirmation
1 Complex Movement Disorder ADCY5 de-novo gain of function mutation yes Yes
2 Lymphoproliferative Disorder Plausible inherited candidate causative mutations in 
GIMAP8
yes not performed
3 Inflammatory Bowel Disease Plausible inherited candidate causative mutations in 
MST1R
yes not performed
4 Fibromyxoid sarcoma No cause identified no N/A
5 Immunodeficiency No cause identified no N/A
6 Lipomatosis and Vasculitis Plausible inherited candidate causative mutations in 
NRIP1
yes not performed
7 Skin and Neurological Disorder Potential, unconfirmed, diagnosis of subtype of 
Epidermolysis Bullosa due to inherited mutations in 
DST1
yes Ongoing
8 Developmental Delay No cause identified no N/A
9 Epileptic Encephalopathy KCNB1 de-novo missense mutation and confirmed 
KV2.1 dysfunction
yes Yes
10 Developmental Delay Plausible inherited candidate causative mutations in 
SYNPO
yes ND
11 Familial Coronary Artery Disease Plausible inherited candidate causative mutation in TDG yes Ongoing
12 Muscular Atrophy No cause identified no N/A
13 Infantile Seizures No cause identified no N/A
14 Recurrent Fever Potential, unconfirmed, diagnosis of subtype of Chédiak–
Higashi syndrome due to inherited mutation in LYST
yes N/A
15 Congenital Hypertrichosis Known pathogenic de-novo ABCC9 mutation identified yes yes
16 Suspected autosomal dominant Opitz 
G/BBB
ongoing N/A N/A
17 Plastic Bronchitis ongoing N/A N/A
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